Stock screenerAll disclosures →
EDGAR →
GRAL
Conviction 88HealthcareScan · Wed, Sep 23, 2026GRAIL, Inc. (GRAL) closed at $108.52 (+0.51%) on Sep 23, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 81, RS Rating 99, -6.5% from its 52-week high, +22.1% year to date. Sector: Healthcare · SERVICES-MEDICAL LABORATORIES.
GRAL$108.52+0.51%
ResistanceSupportVol 14Insider sell11
2
Vol MA14 1.38M
Jun 24Jul 13Jul 30Aug 17Sep 3Sep 22
Price108.52
Change+0.51%
Gap-1.13%
Rel volume3.27×
Avg volume1.14M
Avg $ vol99.93M
SMA 2081.97
SMA 5075.41
SMA 20072.33
Price vs 50+43.90%
Price vs 200+50.03%
MA stackbullish
50/200 crossgolden · 8d
Supertrendup · 86.73
RSI (14)81
MACD hist2.71
MACD crossbull · 1d
Stoch %K / %D90 / 86
ADX (14)28
+DI / −DI44 / 8
RSI divergence—
MACD divergence—
ATR %5.99%
ADR %6.12%
52w high116.06
52w low43.03
From 52w high-6.50%
Above 52w low+152.20%
New 52w highNo
SqueezeOff
Bollinger width43.93%
%B1.24
Donchian pos89.62%
Donchian high112.58
Donchian low73.46
AVWAP (52w high)66.32
vs AVWAP high+63.62%
AVWAP (52w low)63.28
vs AVWAP low+71.49%
OBV trendUp
Chaikin MF (20)0.11
Today vs 20d3.27×
Avg vol (14d)1.38M
Avg vol (20d)1.14M
Avg $ vol (20d)99.93M
Market cap4.85B
RS Rating99 / 99
RS 3m (vs SPY)+72.16%
RS 6m (vs SPY)+102.88%
RS line new highYes
Trend template5/8
Technical rank98.6
1 week+43.00%
1 month+36.43%
3 months+77.58%
6 months+120.88%
1 year+160.55%
YTD+22.11%
P/E-11.87
P/B1.91
P/S32.94
P/FCF-16.16
EPS-11.11
Div yield—
ROE-16.06%
ROA-14.36%
Debt/Eq—
Current10.95
EV/EBITDA—
Gross margin—
Net margin-277.47%
Rev growth17.18%
EPS growth79.85%
Price target82.33
Target upside-24.13%
Analyst ratingBuy
Institutional89.92%
Ent. value4.79B
Revenue44.69M
Net income-110.25M
Gross profit—
Free cash flow-299.92M
IndustrySERVICES-MEDICAL LABORATORIES
ExchangeNasdaq
Shares out42.92M
Employees910
ListedWed, Jun 12, 2024
Free float34.82M
Float %89.3%
Short interest8.51M
Days to cover12.3d
Short volume—
Squeeze score100 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$2.56 vs −$2.91
Last surprise+12.0% beat
Setup gradeA+
Conviction88 / 100
Pattern quality—
Tech rank98.6 / 100
Group rank68 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance84.25
Support63.56
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Grail Surges After FDA Advisors Back Its Cancer-Finding Blood TestYahoo Finance · Thu, Sep 24, 2026
- Dow Jones Futures Fall As Treasury Yields, Oil Prices Keep Rising. Meta, Everpure, Grail Are Early Movers.Yahoo Finance · Thu, Sep 24, 2026
- The Holy Grail In Cancer? FDA Panel Backs Blood TestsYahoo Finance · Wed, Sep 23, 2026
- FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection TestYahoo Finance · Wed, Sep 23, 2026
- GRAIL Stock Jumped 34% Yesterday. The FDA Just Told Its Investors Why.Tikr · Tue, Sep 22, 2026
- GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval HopesStocktwits · Mon, Sep 21, 2026
- Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood TestYahoo Finance · Mon, Sep 21, 2026
- FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This WeekStocktwits · Mon, Sep 21, 2026
Congress activity
Disclosed STOCK Act trades in GRAL
No recent disclosed trades by Congress in GRAL. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in GRAL · open-market 9 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Freidin Aaron Chief Financial Officer · Common Stock · 2026-09-21 | Sell | 1.78K | $164K | 2026-09-21 | 2026-09-23 |
Freidin Aaron Chief Financial Officer · Common Stock · 2026-09-21 | Sell | 1.8K | $169K | 2026-09-21 | 2026-09-23 |
Freidin Aaron Chief Financial Officer · Common Stock · 2026-09-21 | Sell | 521 | $49K | 2026-09-21 | 2026-09-23 |
Ofman Joshua J. Chief Executive Officer · Common Stock · 2026-09-21 | Exercise | 26.45K | $370K | 2026-09-21 | 2026-09-23 |
Ofman Joshua J. Chief Executive Officer · Common Stock · 2026-09-21 | Sell | 2.13K | $196K | 2026-09-21 | 2026-09-23 |
Ofman Joshua J. Chief Executive Officer · Common Stock · 2026-09-21 | Sell | 1.45K | $136K | 2026-09-21 | 2026-09-23 |
Ofman Joshua J. Chief Executive Officer · Common Stock · 2026-09-21 | Sell | 37.75K | $3.6M | 2026-09-21 | 2026-09-23 |
Ofman Joshua J. Chief Executive Officer · Common Stock · 2026-09-21 | Sell | 6.2K | $598K | 2026-09-21 | 2026-09-23 |
Ofman Joshua J. Chief Executive Officer · Common Stock · 2026-09-21 | Sell | 1.4K | $137K | 2026-09-21 | 2026-09-23 |
Ofman Joshua J. Chief Executive Officer · Common Stock · 2026-09-21 | Sell | 421 | $42K | 2026-09-21 | 2026-09-23 |
SEC filings
EDGAR filings in GRAL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.